Stay updated on Selpercatinib in RET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.

Latest updates to the Selpercatinib in RET+ NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has updated its date references, removing older dates from January 2025 and adding new dates in February 2025.SummaryDifference0.3%
- Check30 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.6%
- Check44 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.6%
- Check52 days agoChange DetectedNew updates include the addition of the Jeroen Bosch Hospital and the Abdurrahman Yurtaslan Ankara Oncology Hospital, along with a revision to version 2.14.2, while previous entries related to Eli Lilly and the earlier version 2.14.1 have been removed.SummaryDifference1%
- Check66 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.0%
- Check73 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in this functionality.SummaryDifference0.1%
Stay in the know with updates to Selpercatinib in RET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.